UroGen: Opportunity Builds As Rough Patch Gets Brutal
Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56
UroGen Pharma Ltd (URGN) (Q3 2026) Earnings Call Highlights: Zysturi's 35% Sequential Surge and ...
UroGen Pharma Ltd. Q3 2026 Earnings Call Summary
Earnings Beat Might Change The Case For Investing In UroGen Pharma (URGN)
Urogen Pharma Q3 Earnings Call Highlights
The Gel That Became a Business
UroGen (URGN) Q3 2026 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript
UroGen Pharma (NASDAQ:URGN) Falls After Q3 Revenue Miss and JELMYTO Guidance Cut
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
UroGen Pharma Q3 2026 Earnings Call Transcript
UroGen Pharma Q3 EPS $(0.03) Misses $0.14 Estimate, Sales $89.001M Miss $89.918M Estimate
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma Shares Results From 5-Year Follow-Up Study On Olympus
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
Why UroGen Pharma (URGN) Is Getting Fresh Attention Now
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.